Abstract:

Objective To observe the efficacy and safety of recombinant human endostatin（Endostar） combined with concurrent intensity-modulated radiation therapy （IMRT） for inoperable local advanced non-small cell lung cancer （NSCLC） in elderly patients. Methods A total of 40 elderly patients with inoperable local advanced NSCLC confirmed by pathology were randomly divided into a control group and trial group，each with 20 cases. Patients in the trial group received IMRT，and the dosage for primary tumor and mediastinal lymph node metastasis was DT 60-66 Gy，30-33 measurement unit for 6-7 weeks；in addition，these patients concurrently received 15 mg Endostar by intravenous drip once per day for 14 days. Control patients received IMRT alone，using the same method and dosage as in the trial group. Efficacy and survival were compared between the two patient groups. Results The trial and control groups showed no significant difference between ORR （75.0% vs 80.0%，P=0.326），DCR（100% vs 90.0%，P=0.031），mPFS （9.4 vs 6.8 months，P=0.286） or mOS （17.5 vs 14.1 months，P=0.052）. The two groups experienced similar major toxic effects，most of which were G1/2. Conclusion Endostar combined with concurrent IMRT showed a tendency toward longer median survival than IMRT alone for treating inoperable local advanced NSCLC in elderly patients.

Key words: Lung neoplasms, Inoperable, Local advanced, Elderly, Recombinant human endostatin, Intensity-modulated radiation therapy, Efficacy